Atlas Trials

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib

Clinical trial NCT02115386 · TERMINATED

Trial details

NCT number
NCT02115386
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Start date
2015-12-17
Primary completion
2016-10-31
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.